Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target ...

To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy -; similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory ...

Issued on behalf of PlantX Life Inc. VANCOUVER – USA News Group News Commentary – With over 100 million Americans facing ...

Calling the decision not to disclose the genetic results “certainly troubling” and “ethically fraught,” George Perry, editor ...

On Tuesday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $319.66 which represents a slight increase of $2.92 or 0.92% from the prior close of $316.74. The stock opened at $315.24 and ...

Ionis has five FDA-approved drugs and promising upcoming approvals. See more about IONS stock and why it warrants a Buy ...

Amgen AMGN will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company ...

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Amgen is a significant win for IPG Mediabrands after Amazon moved its massive media business from Initiative to WPP and ...

Bernstein analyst Courtney Breen maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $380.00.